Literature DB >> 28828522

Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.

Dan Călugăru1, Mihai Călugăru2.   

Abstract

Entities:  

Keywords:  Aflibercept; Central choroidal thickness; Central macular thickness; Polypoidal choroidal vasculopathy; Treat-and-extend regimen

Mesh：

Substances：

Year:  2017        PMID： 28828522     DOI： 10.1007/s00417-017-3784-9

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  10 in total

1.  Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes.

Authors:  Sylvie Julien; Antje Biesemeier; Tatjana Taubitz; Ulrich Schraermeyer
Journal:  Br J Ophthalmol       Date:  2014-01-23       Impact factor: 4.638

2.  Long-term Outcomes of Aflibercept Treatment for Neovascular Age-related Macular Degeneration in a Clinical Setting.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2016-12-23       Impact factor: 5.258

3.  Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2016-11-11       Impact factor: 5.258

4.  Six-year outcomes of antivascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy.

Authors:  Taiichi Hikichi
Journal:  Br J Ophthalmol       Date:  2017-05-25       Impact factor: 4.638

5.  Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.

Authors:  Masahiro Morimoto; Hidetaka Matsumoto; Kensuke Mimura; Hideo Akiyama
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-01       Impact factor: 3.117

6.  Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2016-12-05       Impact factor: 5.258

7.  Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.

Authors:  Magda Gharbiya; Filippo Cruciani; Cesare Mariotti; Francesca Grandinetti; Marco Marenco; Vittorio Cacace
Journal:  J Ocul Pharmacol Ther       Date:  2015-06-03       Impact factor: 2.671

8.  Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy.

Authors:  Seongyong Jeong; Min Sagong
Journal:  Br J Ophthalmol       Date:  2016-09-05       Impact factor: 4.638

9.  Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid.

Authors:  Glenn J Jaffe; Peter K Kaiser; Desmond Thompson; Andrea Gibson; Namrata Saroj; Robert Vitti; Alyson J Berliner; Jeffrey S Heier
Journal:  Ophthalmology       Date:  2016-06-28       Impact factor: 12.079

10.  Indocyanine green angiographic and optical coherence tomographic findings support classification of polypoidal choroidal vasculopathy into two types.

Authors:  Akiyuki Kawamura; Mitsuko Yuzawa; Ryusaburo Mori; Miho Haruyama; Koji Tanaka
Journal:  Acta Ophthalmol       Date:  2013-07-15       Impact factor: 3.761
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.